<--- Back to Details
First PageDocument Content
Gilead Sciences / Pharmacology / Non-nucleoside reverse transcriptase inhibitors / Organofluorides / Bristol-Myers Squibb / Reverse-transcriptase inhibitor / Emtricitabine / ATC code J05 / Antiretroviral drug / Chemistry / Organic chemistry / Fixed dose combination
Date: 2014-11-20 04:23:49
Gilead Sciences
Pharmacology
Non-nucleoside reverse transcriptase inhibitors
Organofluorides
Bristol-Myers Squibb
Reverse-transcriptase inhibitor
Emtricitabine
ATC code J05
Antiretroviral drug
Chemistry
Organic chemistry
Fixed dose combination

Kentucky AIDS Drug Assistance Program Formulary

Add to Reading List

Source URL: www.chfs.ky.gov

Download Document from Source Website

File Size: 163,25 KB

Share Document on Facebook

Similar Documents

A Day in Life at BMS Welcome to A Day in Life at BMS where you will meet leaders from our R&D organization and learn more about research and development at Bristol-Myers Squibb, as well as network with our scientists. To

DocID: 1vrK6 - View Document

NoIN THE Supreme Court of the United States BRISTOL-MYERS SQUIBB COMPANY, PETITIONER,

DocID: 1tuCc - View Document

Bristol-Myers Squibb Co. v. Superior Court of Cal., San Francisco Cty)

DocID: 1tut4 - View Document

September 2003 USA Bristol-Myers Squibb Medical Imaging

DocID: 1sKnx - View Document

May 2003 Bristol-Myers Squibb Medical Imaging 331 Treble Cove Road N. Billerica, Massachusetts 01862

DocID: 1sC8T - View Document